Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Shailender Bhatia's publication output changed over time?
ScholarIQpublication output · 2012–2017
Output grew100% over the shown period — from 1 works in 2012 to 2 in 2017.
1
2
20122017
What are the most-cited papers on Shailender Bhatia?
ScholarIQmost cited works
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith D. Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan Parker, Shruti Agrawal, S. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton
New England Journal of Medicine. 20128,035 CitationsOPEN ACCESS
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov, Alexis Desrichard, Walter J. Urba, Jennifer S. Sims, F. Stephen Hodi, Salvador Martín‐Algarra, Rajarsi Mandal, William H. Sharfman, Shailender Bhatia, Wen-Jen Hwu, Thomas F. Gajewski, Craig L. Slingluff, Diego Chowell, Sviatoslav M. Kendall, Han Chang, Rachna Shah, Fengshen Kuo, Luc G.T. Morris, John-William Sidhom, Jonathan P. Schneck, Christine E. Horak, Nils Weinhold, Timothy A. Chan
Cell. 20172,584 CitationsOPEN ACCESS
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean-Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, René González, Ragini R. Kudchadkar, Michael Smylie, Nicolás Meyer, Laurent Mortier, Michael B. Atkins, Georgina V. Long, Shailender Bhatia, Célèste Lebbé, Piotr Rutkowski, Kenji Yokota, Naoya Yamazaki, Tae M. Kim, Veerle de Pril, Javier Sabater, Anila Qureshi, James Larkin, Paolo A. Ascierto
New England Journal of Medicine. 20172,214 CitationsOPEN ACCESS
Related on ScholarIQ
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Paper
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Paper
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Paper
Immunotherapy and Immune Responses
Topic
Bacteriophages and microbial interactions
Topic
Cancer Immunotherapy and Biomarkers
Topic